摘要
免疫疗法在恶性肿瘤治疗中的应用正日益受到关注。嵌合抗原受体(CAR)技术是一种新兴的免疫疗法,在血液肿瘤的治疗上具有巨大的潜力。嵌合抗原受体T细胞免疫疗法(CAR-T)可通过特异性识别靶抗原来杀伤骨髓瘤细胞,使治疗复发难治性多发性骨髓瘤成为可能。该文重点对CAR-T在多发性骨髓瘤治疗方面的研究进展作一综述,并对可能作为CAR-T治疗多发性骨髓瘤的靶抗原进行了分析。
Application of immunotherapy in malignant tumor has widely been focused. Chimeric antigen receptor is one of the emerging immunotherapy and has enormous potentiality to treat hematologic neoplasms. Chimeric antigen receptor-modified T cells（ CAR-T） may contribute to treat multiple myeloma as CAR-T can kill target myeloma cells by means of identifying the target antigen. In this article, the research advances of CAR-T in treating multiple myeloma were reviewed,and the antigens which may be an effective target for CAR-T in eliminating myeloma cells were analyzed.
作者
刘奕晨
孙志强
郑方
LIU Yichen SUN Zhiqiang ZHEN Fang(Graduate School, Guizhou Medical University ,Guiyang, Guizhou 550000 China Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Gaizhou 550000, China Department of Hematology, Shenzhen Hospital Affiliated to Southern Medical University, Shenzhen, Guangdong 51S000 , China Department of Hematology, Baiyun Hospital Affiliated to Guizhou Medical University, Guiyang, Guizhou 550000 , China)
出处
《安徽医药》
CAS
2017年第6期978-982,共5页
Anhui Medical and Pharmaceutical Journal
